TOKYO, Mar 31 (Pulse News Wire) – Teijin Limited (3401.T) revised its fiscal year 2026 earnings forecast due to delays in asset sales and restructuring efforts in its pharmaceutical division. The company previously projected consolidated revenue of ¥860.0 billion, operating profit of ¥5 billion, and net profit of ¥--¥10.00 billion.
However, based on recent performance trends, Teijin now expects operating profit to range from ¥--¥75.00 billion to ¥--¥85.00 billion and net profit to range from ¥--¥85.00 billion to ¥--¥95.00 billion. The revision follows the postponement of the sale of shares in Dupont Teijin Advanced Papers (Asia) Limited and Teijin Advanced Paper Co., Ltd. to the fiscal year ending March 2027 instead of March 2026.
Additionally, Teijin is reassessing its diabetes treatment agent sales rights within its subsidiary Teijin Pharma, potentially leading to impairment losses. Furthermore, the company is reviewing the recoverability of deferred tax assets, which could result in partial utilization. Despite these challenges, Teijin maintains its dividend policy, planning to distribute ¥50 per share for the fiscal year 2026, including an interim dividend of ¥25 per share.
Forecast revision — FY2026/3Downward revision
| Metric | Prior | Revised | Change |
|---|---|---|---|
| Revenue | ¥860,000M | ¥860,000M | |
| Op. profit | ¥25,000M | ¥25,000M | |
| Net profit | ¥-10,000M | ¥-85,000M |
Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.